| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Aspartic acid calcium does not target a specific biological receptor but provides bioavailable calcium and aspartate. Calcium is essential for bone health, muscle contraction, nerve transmission, and intracellular signaling. L-Aspartate is involved in the urea cycle, gluconeogenesis, and neurotransmitter synthesis. The chelated form is designed to enhance calcium absorption and bioavailability compared to inorganic calcium salts.
|
|---|---|
| ln Vitro |
L-Aspartate (L-Aspartate) is one of the twenty-three proteinaceous amino acids and the L isomer of aspartic acid. Proteins directly incorporate L-aspartic acid.
In vitro, aspartic acid calcium is used as a source of calcium and aspartate in cell culture studies. It is a chelate where calcium is attached to L-aspartic acid. The compound's solubility and bioavailability make it suitable for studying calcium-dependent processes, including osteoblast differentiation, neuronal signaling, and muscle cell function. It can also be used to supplement cell culture media with bioavailable calcium. |
| ln Vivo |
In vivo, aspartic acid calcium has been studied for its effects on bone metabolism, mineral absorption, and neuromuscular function. As a calcium supplement, it may support bone health and prevent calcium deficiency. The aspartate component may also influence neurotransmitter levels and energy metabolism. However, detailed pharmacological studies are limited, as it is primarily used as a nutritional supplement and research tool.
|
| Enzyme Assay |
For in vitro cell-based assays, aspartic acid calcium is typically tested on osteoblasts, neuronal cells, or muscle cells. Cells are treated with the compound at various concentrations (typically 10-1000 µM calcium equivalent) for 24-72 hours. Calcium uptake is measured using fluorescent calcium indicators (e.g., Fluo-4) or atomic absorption spectroscopy. Osteogenic differentiation is assessed by alkaline phosphatase staining and mineralization assays.
|
| Cell Assay |
For in vitro enzyme assays, aspartic acid calcium can be used to study calcium-dependent enzymes or to provide aspartate as a substrate for enzymes such as aspartate aminotransferase. The compound is incubated with the enzyme and its cofactors in a suitable buffer. Enzyme activity is measured by monitoring substrate conversion using spectrophotometric or fluorometric methods.
|
| Animal Protocol |
For in vivo animal experiments, aspartic acid calcium is typically administered orally to rodent models of calcium deficiency or osteoporosis. The compound is given at doses ranging from 10-100 mg calcium equivalent per kg body weight daily for 4-12 weeks. Bone mineral density is measured by DEXA or micro-CT. Serum calcium, phosphorus, and bone turnover markers are measured. Histomorphometric analysis of bone tissue is performed to evaluate efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for aspartic acid calcium are limited. As a small molecule with a molecular weight of 171.16 g/mol and formula C₄H₅CaNO₄, it is expected to be rapidly absorbed from the gastrointestinal tract. Calcium from the chelate is released and absorbed via active transport and passive diffusion. The aspartate component is metabolized via the citric acid cycle. The compound's pharmacokinetics are similar to other calcium supplements.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org Toxicological data for aspartic acid calcium indicate that it is generally well-tolerated at recommended doses. As a calcium supplement, excessive intake may cause hypercalcemia, gastrointestinal disturbances, or kidney stones. The compound is classified as a research-grade reagent and nutritional supplement, not as a therapeutic drug. Standard safety practices should be followed when handling. |
| References | |
| Additional Infomation |
L-Calcium aspartate is an organic molecular entity. It is one of the common non-essential amino acids, existing in its L-form. It is found in both plants and animals, particularly in sugarcane and sugar beets. It may be a neurotransmitter.
Aspartic acid calcium is a research-use only compound and has not been approved as a therapeutic drug. It is also known as Calcium L-aspartate. Its molecular weight is 171.16, and its formula is C₄H₅CaNO₄. The compound is available from various research chemical suppliers for studies of mineral absorption, bone metabolism, and bioenergetics. |
| Molecular Formula |
C4H5CANO4
|
|---|---|
| Molecular Weight |
171.17
|
| Exact Mass |
170.984
|
| CAS # |
10389-09-0
|
| Related CAS # |
L-Aspartic acid;56-84-8;L-Aspartic aicd sodium;3792-50-5;L-Aspartic acid potassium;1115-63-5
|
| PubChem CID |
30465
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H](C(=O)[O-])N)C(=O)[O-].[Ca+2]
|
| InChi Key |
OPSXJNAGCGVGOG-DKWTVANSSA-L
|
| InChi Code |
InChI=1S/C4H7NO4.Ca/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+2/p-2/t2-;/m0./s1
|
| Chemical Name |
calcium;(2S)-2-aminobutanedioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~584.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8421 mL | 29.2107 mL | 58.4215 mL | |
| 5 mM | 1.1684 mL | 5.8421 mL | 11.6843 mL | |
| 10 mM | 0.5842 mL | 2.9211 mL | 5.8421 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
